Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: Impact of imatinib on relapse and survival

M. J. Burke, B. Trotz, X. Luo, K. S. Baker, D. J. Weisdorf, J. E. Wagner, M. R. Verneris

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

The utility of imatinib in either the pre- or post-transplant period for Ph chromosome-positive (Ph+) ALL is uncertain. In addition, there have been recent concerns regarding imatinib and cardiac toxicity. We investigated the outcome of 32 patients with Ph+ ALL who received an allo-hematopoietic cell transplant (HCT) at the University of Minnesota between 1999 and 2006. The median age at HCT was 21.9 years (range: 2.8-55.2). All patients were conditioned with CY and TBI. GVHD prophylaxis was CsA based. Of the 32 patients, 15 received imatinib therapy pre- or post-HCT (imatinib group) and 17 patients received either no imatinib (n=11) or only after relapse (n=6) (non-imatinib group). Overall survival, relapse-free survival and relapse at 2 years was 61, 67 and 13% for the imatinib group as compared with 41, 35 and 35% for the non-imatinib group (P=0.19, 0.12 and 0.20, respectively). Cardiac toxicity and TRM at 2 years were similar between groups. Thus, patients treated with imatinib in either the pre- or post-transplant setting had trends toward improved outcomes and no increase in cardiac toxicity. We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalBone marrow transplantation
Volume43
Issue number2
DOIs
StatePublished - 2009

Bibliographical note

Funding Information:
This work was supported by the Children’s Cancer Research.

Fingerprint Dive into the research topics of 'Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: Impact of imatinib on relapse and survival'. Together they form a unique fingerprint.

Cite this